Literature DB >> 8162734

Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy.

S R Weingarten1, M S Riedinger, G Varis, M S Noah, M J Belman, R D Meyer, A G Ellrodt.   

Abstract

PURPOSE: Few available data exist to define either the medically necessary duration of parenteral antimicrobial therapy or length of stay for hospitalized patients with pneumonia. Therefore, we investigated the potential safety and effectiveness of a practice guideline recommending early conversion of low-risk patients with pneumonia from parenteral to oral antimicrobial therapy and early hospital discharge. PATIENTS AND METHODS: The practice guideline was studied retrospectively in 503 hospitalized patients with pneumonia at a teaching community hospital.
RESULTS: Thirty-three percent of patients with pneumonia were classified as at low risk for complications and potentially suitable for early conversion to oral antimicrobial therapy according to the guideline. Were the guideline to have been used to guide patient discharge decisions, 619 additional bed-days would have been made available to accommodate incoming patients. A consensus among physician reviewers led to the judgment that quality of care would not have worsened for 98.2 percent of low-risk patients had they been switched to oral antimicrobial therapy on the third hospital day, nor would quality of care have been worsened for 93.4 percent of low-risk patients had they been discharged on the fourth hospital day.
CONCLUSION: The practice guideline that we studied has the potential to safely reduce the duration of parenteral antimicrobial therapy and length of hospital stay for selected low-risk patients with pneumonia. The guideline should be studied in a prospective clinical trial.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162734     DOI: 10.1378/chest.105.4.1109

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Authors:  B G Feagan; T J Marrie; C Y Lau; S L Wheeler; C J Wong; M K Vandervoort
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Ongoing issues in pneumonia care: when to admit, how to treat and the role of oral therapy.

Authors:  A C Shillington
Journal:  J Med Syst       Date:  2000-10       Impact factor: 4.460

3.  Do practice guidelines augment drug utilisation review?

Authors:  E A Chrischilles; K Gondek
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 4.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 5.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

6.  Assessment of the use of cefixime for switch therapy.

Authors:  D E Low
Journal:  Infection       Date:  1995       Impact factor: 3.553

Review 7.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 8.  Practical considerations and guidelines for the management of community-acquired pneumonia.

Authors:  R G Finch; M A Woodhead
Journal:  Drugs       Date:  1998-01       Impact factor: 11.431

9.  Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.

Authors:  D Genné; H H Siegrist; L Humair; B Janin-Jaquat; A de Torrenté
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.